NCT00258570Recruiting
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
The purposes of this study are: * to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; * to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 23 Nov 2005
- Start date
- Jan 2003
- Primary completion date
- Jul 2035
- Lead sponsor
- University of Pittsburgh
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT00258570
What you commit to
- Study type: Observational
- Planned participants: 2000
- From Jan 2003 to the primary completion date, Jul 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Under 18 years of age
Other
- Non-fibrotic ILD
Who the study is looking for
- 18 years of age or older
- Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest X-ray, and computed tomography (CT) scans.
- Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.